Frontal fibrosing alopecia (FFA) typically affects post-menopausal women. However, approximately 20% of female patients are pre-menopausal and 10% are men with distinctive presentation.

Disease pattern and therapeutic options differ among patients, therefore treatment strategy has to be individualised.

Fortunately, newer and targeted treatments are available now, compared to when it was first reported in the 90s.

​

Articles on Scarring Alopecia: 

​

1) JOURNAL EDITOR'S PICK OF THE YEAR 2018:

5 alpha-reductase inhibitor treatment for frontal fibrosing alopecia: An evidence-based treatment update. (JEADV)

​

2) Reply: Effectiveness of dutasteride in large series of patients with frontal fibrosing alopecia in real clinical practice. (JAAD)

​

3) Frontal fibrosing alopecia in breast cancer patients on aromatase-inhibitor. (JEADV)

​

4) Prostaglandin analogue for treatment of eyebrow loss in frontal fibrosing alopecia: 3 cases with different outcomes. (JEADV)

​

5) Wood's light examination for assessment in frontal fibrosing alopecia: A manoeuvre to enhance the hairline. (JAAD)

​

6) A prospective pilot study of narrowband UV-B treatment of lichen planopilaris (JAAD) 

​

7) Keratosis follicularis spinulosa decalvans-like cicatricial alopecia in a patient with cardiofasciocutaneous syndrome. (CED)

​

8) Updates in therapeutics for folliculitis decalvans: A systemic review with evidence-based analysis. (JAAD)

​

Frontal fibrosing alopecia (FFA) typically affects post-menopausal women. However, approximately 20% of female patients are pre-menopausal and 10% are men with distinctive presentation.